SCHEMBL22719743

SCHEMBL22719743

Cc1ccc(Br)cc1Nc1ccc(C(F)(F)F)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 2/20 0.60
▸ TRPV1 Q8NER1 4/20 0.45
▸ XPO1 O14980 1/20 0.43
▸ THRB P10828 1/20 0.42
▸ POLB P06746 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ RIPK2 O43353 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ MAPK10 P53779 1/20 0.40
▸ PRKAB2 O43741 1/20 0.40
▸ PRKAG1 P54619 1/20 0.40
▸ PRKAA2 P54646 1/20 0.40
▸ PRKAA1 Q13131 1/20 0.40
▸ PRKAG3 Q9UGI9 1/20 0.40
▸ PRKAG2 Q9UGJ0 1/20 0.40
▸ PRKAB1 Q9Y478 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ TAS2R14 Q9NYV8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9358482 0.83 TEAD1 (0.55) TEAD1TRPV1XPO1POLBGAA
SCHEMBL23994048 0.80 TRPV1 (0.43) TEAD1TRPV1THRBPOLBGAA
SCHEMBL22719666 0.80 TEAD1 (0.52) TEAD1TRPV1XPO1POLBGAA
SCHEMBL29505063 0.80 TEAD1 (0.52) TEAD1TRPV1XPO1POLBGAA
SCHEMBL9358514 0.78 ALDH1A1 (0.50) TEAD1GAAKDRMAPT
SCHEMBL22719665 0.76 TEAD1 (1.00) TEAD1
SCHEMBL22719790 0.76 TEAD1 (1.00) TEAD1
SCHEMBL22719792 0.76 TEAD1 (1.00) TEAD1
SCHEMBL29504946 0.76 TEAD1 (1.00) TEAD1
SCHEMBL29504992 0.76 TEAD1 (1.00) TEAD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11925651-B2 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-03-12 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2023-05-11 — — US disclosed
US-11458149-B1 TEAD inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-10-04 — — US disclosed
CN-114502540-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2022-05-13 — — CN disclosed
EP-3976192-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2022-04-06 — — EP disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243423-A1 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148061-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885TRPV1 3000/4885XPO1 273/4885
US-11925651-B2 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885TRPV1 3000/4885XPO1 273/4885
US-11458149-B1 TEAD inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885TRPV1 3000/4885XPO1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback